References
Zwarthoed C, El-Galaly TC, Canepari M, Ouvrier MJ, Viotti J, Ettaiche M, Viviani S, Rigacci L, Trentin L, Rusconi C, Luminari S, Cantonetti M, Bolis S, Borra A, Darcourt J, Salvi F, Subocz E, Tajer J, Kulikowski W, Malkowski B, Zaucha JM, Gallamini A (2017) Prognostic value of bone marrow tracer uptake pattern in baseline PET scan in Hodgkin lymphoma: results from an international collaborative study. J Nucl Med. doi:10.2967/jnumed.116.184218
Adams HJ, Nievelstein RA, Kwee TC (2015) Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma. Blood Rev 29(6):417–425. doi:10.1016/j.blre.2015.06.003
Adams HJ, Nievelstein RA, Kwee TC (2016) Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy. Ann Hematol 95(1):1–9. doi:10.1007/s00277-015-2529-2
Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7(11):1630–1636. doi:10.1200/jco.1989.7.11.1630
Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med 339(21):1506–1514. doi:10.1056/NEJM199811193392104
Ferme C, Bastion Y, Brice P, Lederlin P, Divine M, Gabarre J, Assouline D, Ferrant A, Berger F, Lepage E (1997) Prognosis of patients with advanced Hodgkin’s disease: evaluation of four prognostic models using 344 patients included in the group d’Etudes des Lymphomes de l’Adulte study. Cancer 80(6):1124–1133
El-Galaly TC, Hutchings M, Mylam KJ, Brown Pde N, Bukh A, Johnsen HE, Kamper P, Loft A, Iyer V, Gormsen LC, Nielsen AL, Bogsted M, d'Amore F (2014) Impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement. Leuk Lymphoma 55(10):2349–2355. doi:10.3109/10428194.2013.875169
Author information
Authors and Affiliations
Contributions
Hugo J.A. Adams: study design, article writing, and final approval of the manuscript.
Thomas C. Kwee: study design, article writing, and final approval of the manuscript.
Corresponding author
Ethics declarations
Funding
This work was financially supported by an Alpe d’HuZes/Dutch Cancer Society Bas Mulder Award for T.C.K. (grant number 5409).
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Adams, H.J., Kwee, T.C. Assessing baseline bone marrow status in advanced-stage Hodgkin lymphoma: does it have any purpose?. Ann Hematol 96, 1047–1048 (2017). https://doi.org/10.1007/s00277-017-2990-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-017-2990-1